Q3 revenue consensus $7.85M. Cash, cash equivalents, available-for-sale securities, and restricted cash were approximately$23.3 millionas ofSeptember 30, 2024, of which$11.4 millionwas subject to certain restrictions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Bionano Genomics adjourns Special Meeting of Stockholders
- Alphabet, Meta initiated: Wall Street’s top analyst calls
- Bionano lowered 2024 revenue outlook to $32M-$36M from $36M-$40M
- BTIG downgrades Bionano to Neutral after fourth workforce reduction
- Bionano Genomics lays off 45% of staff, or 84 employees